Benchmark Reiterates Kamada Buy Rating After Disappointing Q1 Results
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Benchmark analysts reiterated a Buy rating on Kamada Ltd. stock on 19 May 2026, maintaining a price target of $10.00. The affirmation follows the company's reported first-quarter results, which missed analyst consensus on earnings per share. Kamada's stock closed at $7.45 on the prior trading day, representing a discount of more than 25% to Benchmark's target. The firm cited sustained growth in the core immunoglobulin franchise as the primary driver for its continued bullish stance.
The analyst's reaffirmation arrives amid a challenging period for small-to-mid cap biopharma stocks in 2026. The Nasdaq Biotechnology Index (NBI) is down 4.2% year-to-date, pressured by persistent inflation and elevated interest rates. Kamada's specific Q1 miss, a 31% shortfall against the consensus EPS forecast, typically triggers rating downgrades or target reductions. Benchmark's decision to hold firm signals a belief that quarterly volatility is less relevant than long-term strategic positioning in plasma-derived therapies. The last major analyst action on Kamada was a downgrade by a peer firm in November 2025 following guidance revision.
A critical catalyst for the current valuation assessment is the commercial ramp of Kamada's intravenous immunoglobulin (IVIG) products in the United States. The company successfully expanded its distribution footprint in 2025, securing contracts with several major group purchasing organizations. This institutional access is translating into consistent prescription growth, which Benchmark views as outweighing transient manufacturing cost pressures that impacted Q1 margins. The immunoglobulin market itself is growing at a compound annual rate of approximately 6.5% globally, driven by increasing diagnosis rates for primary immunodeficiency disorders.
Kamada reported Q1 2026 revenue of $38.7 million, a 9% increase year-over-year. The growth was led by its proprietary products segment, which grew 14% to $29.1 million. However, gross profit margin contracted to 42% from 46% in the year-ago quarter, a key factor in the earnings miss. The company ended the quarter with $67 million in cash and cash equivalents. Its current market capitalization stands near $420 million, trading at an enterprise-value-to-sales multiple of 2.1x. This is below the peer group median of 2.8x for commercial-stage plasma product companies like Grifols SA and CSL Limited.
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $38.7M | $35.5M | +9.0% |
| Gross Margin | 42% | 46% | -400 bps |
| Cash & Equivalents | $67M | $72M | -$5M |
Earnings per share came in at a loss of $0.04, missing the consensus forecast for a $0.01 profit. This compares to a profit of $0.03 per share in Q1 2025. The stock's year-to-date performance of -11% underperforms both the NBI and the broader S&P 500 Health Care sector, which is down 3%.
Benchmark's stance suggests a second-order opportunity in undervalued commercial biotechs with entrenched distribution. Firms like ADMA Biologics, which also focuses on immunoglobulins, could see renewed investor scrutiny. ADMA shares are down 15% YTD. Conversely, the reaffirmation may pressure short sellers in Kamada, who hold a short interest equivalent to 4.2% of the float. A sustained rally toward the $10 target could force covering, adding upward momentum. In the plasma sector, stable demand often insulates companies from broader economic cycles, making them a potential defensive rotation target if macro conditions worsen.
A key counter-argument to Benchmark's optimism is Kamada's significant debt load of $55 million. Servicing this debt in a high-rate environment directly pressures net income, a risk not fully reflected in revenue-multiple valuations. the immunoglobulin market faces long-term pricing pressure from payer organizations, which could compress future margins. Flow data indicates institutional investors have been net sellers over the past quarter, while retail buying via platforms like Robinhood has increased slightly, suggesting a divergence in conviction.
The next major catalyst is Kamada's Q2 2026 earnings report, scheduled for early August 2026. Investors will monitor whether gross margins stabilize above 43% and if the immunoglobulin revenue growth rate accelerates sequentially. The company's guidance for full-year 2026 EBITDA, currently projected at $28-$32 million, will be tested. Key technical levels include support at the 200-day moving average of $7.10 and resistance at the $8.50 level, which has capped advances three times in the past year. A break above $8.50 on high volume could signal a technical shift.
Regulatory updates on Kamada's pipeline, including an inhaled alpha-1 antitrypsin therapy for COPD, are expected by late 2026. Positive data could expand the total addressable market beyond the core plasma business. Investors should also watch the 10-year Treasury yield; a sustained decline below 4.0% would improve the discounted cash flow valuation for all growth-sensitive healthcare stocks, including Kamada.
A reiterated Buy rating with an unchanged price target indicates the analyst firm sees no fundamental deterioration in the long-term investment thesis. For shareholders, it suggests holding through near-term volatility is justified if they believe in the company's strategic growth drivers, primarily its immunoglobulin commercial execution. It does not guarantee the stock price will reach the target, but it provides a counter-narrative to selling pressure driven by a single quarterly earnings miss.
Kamada trades at a discount to larger, more diversified plasma leaders. CSL Limited trades at an EV/Sales multiple of 5.4x, while Grifols trades at 1.9x. Kamada's 2.1x multiple sits between them, reflecting its smaller scale and single-country commercial focus for key products. The discount accounts for higher execution risk and less geographic diversification, but also offers greater growth potential if U.S. commercialization succeeds.
The primary risks are pricing pressure from healthcare insurers, potential supply constraints for source plasma, and competition from both established players and new entrants developing subcutaneous or longer-acting immunoglobulin products. Manufacturing costs are highly sensitive to plasma collection costs and facility utilization rates. Any disruption at its Israeli manufacturing facility also poses a concentrated operational risk not faced by competitors with global production networks.
Benchmark's reiterated Buy rating prioritizes Kamada's strategic immunoglobulin growth over near-term earnings volatility.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.